Calcium Signaling — Investment Landscape Analysis

Calcium Signaling in Neurodegeneration — Investment Landscape Analysis

Overview

Calcium Signaling in Neurodegeneration — Investment Landscape Analysis

Overview

Investment Landscape: Calcium Signaling covers the current R&D investment, clinical trial pipeline, and therapeutic approaches targeting calcium signaling dysregulation in neurodegenerative diseases. Calcium homeostasis is critical for neuronal function, and its disruption is implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders["@calcium2022"].

Last updated: 2026-03-15

Executive Summary

Calcium signaling represents a fundamental pathway in neuronal health and disease. Dysregulation of calcium homeostasis contributes to:

• Synaptic dysfunction and loss
• Mitochondrial dysfunction and energy failure
• Activation of apoptotic pathways
• Excitotoxicity
• Protein aggregation

Clinical Trial Pipeline

Overview

Current clinical trials targeting calcium signaling mechanisms remain limited compared to other therapeutic approaches. The focus has been primarily on repurposing existing cardiovascular calcium channel blockers for neurodegenerative indications, with mixed results in clinical trials.

Trial Landscape

| Status | Count |
|--------|-------|
| Recruiting | 5-10 |
| Active, Not Recruiting | 3-5 |
| Completed | 15-20 |
| Terminated/Withdrawn | 10-15 |

Phase Distribution

| Phase | Approximate Trials |
|-------|-------------------|
| Phase 1 | 5-8 |
| Phase 2 | 10-15 |
| Phase 3 | 3-5 |

Therapeutic Approaches

Calcium Channel Blockers

Calcium channel blockers (CCBs) represent the most advanced approach to targeting calcium dysregulation in neurodegeneration:

• L-type calcium channel blockers: Nimodipine, isradipine, flunarizine
• N-type calcium channel blockers: Ziconotide derivatives
• T-type calcium channel blockers: Ethosuximide derivatives

Clinical Status: Several Phase 2/3 trials completed for AD and PD; mixed results

Calcium Homeostasis Modulators

Novel approaches to restore calcium homeostasis:

• SERCA activators: CDN1163, istaroxime
• MCU inhibitors: Novel small molecules in preclinical development
• Calpain inhibitors: MDL-28170, calpeptin

Clinical Status: Mostly preclinical to Phase 1

Calcium-Sensing Receptor Modulators

Targeting extrasynaptic calcium signaling:

• Calcium-sensing receptor agonists: Cinacalcet derivatives
• Positive allosteric modulators: Novel compounds in development

Clinical Status: Early preclinical

Disease-Specific Analysis

Alzheimer's Disease

Calcium dysregulation is an early event in AD pathogenesis, contributing to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology:

• Trial count: 8-12 trials
• Focus: L-type channel blockers, calcium homeostasis restoration
• Key players: Novartis (Clozapine), Axsome (AX-830)
• Gap: Lack of disease-modifying approaches

Parkinson's Disease

Calcium dysregulation contributes to dopaminergic neuron vulnerability:

• Trial count: 5-8 trials
• Focus: T-type channel blockers, mitochondrial calcium modulation
• Key players: FDA approved isradipine for PD (though limited adoption)
• Gap: Need for better [blood-brain barrier](/entities/blood-brain-barrier) penetration

Amyotrophic Lateral Sclerosis

Calcium dysregulation in motor [neurons](/entities/neurons):

• Trial count: 3-5 trials
• Focus: Excitotoxicity modulation
• Key players: Few active programs
• Gap: Significant unmet need

NIH Funding Trends

Annual NIH funding for calcium signaling in neurodegeneration:

• FY2020: 5-40M
• FY2021: 8-42M
• FY2022: 0-45M
• FY2023: 2-48M
• FY2024: 5-50M

Competitive Landscape

Key Players

| Company | Approach | Development Stage | Market Position |
|---------|----------|-------------------|-----------------|
| Novartis | L-type CCB | Phase 2/3 | Established |
| Biogen | Calcium modulation | Phase 1 | Emerging |
| Axsome Therapeutics | Novel mechanisms | Phase 2 | Disruptor |
| NeuroKey | SERCA activators | Preclinical | Early stage |

Investment Opportunities

Research Gaps

Priority Recommendations

Short-Term (1-2 Years)

Medium-Term (2-5 Years)

Long-Term (5-10 Years)

Related Pages

• [Calcium Channel Blockers in Neurodegeneration](/therapeutics/calcium-channel-blockers-neurodegeneration)
• [Calcium Homeostasis Modulators in Neurodegeneration](/therapeutics/calcium-homeostasis-modulators)
• [Calcium Dysregulation in Neurodegeneration](/mechanisms/calcium-dysregulation-neurodegeneration)
• [Alzheimer's Disease Investment Landscape](/diseases/alzheimers-disease-investment-landscape)
• [Parkinson's Disease Investment Landscape](/diseases/parkinsons-disease-investment-landscape)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Calcium Signaling — Investment Landscape Analysis discovered through SciDEX knowledge graph analysis: